520
Views
3
CrossRef citations to date
0
Altmetric
Research Articles

Pharmacophore-based virtual screening, molecular docking and molecular dynamics simulations study for the identification of LIM kinase-1 inhibitors

ORCID Icon, , , ORCID Icon, , ORCID Icon & ORCID Icon show all
Pages 6089-6103 | Received 09 Feb 2022, Accepted 09 Jul 2022, Published online: 21 Jul 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Powsali Ghosh, Ravi Singh, Ankit Ganeshpurkar, Rayala Swetha, Devendra Kumar, Sushil Kumar Singh & Ashok Kumar. (2023) Identification of potential death-associated protein kinase-1 (DAPK1) inhibitors by an integrated ligand-based and structure-based computational drug design approach. Journal of Biomolecular Structure and Dynamics 41:20, pages 10785-10797.
Read now

Articles from other publishers (2)

Hélène Bénédetti & Béatrice Vallée. (2023) LIM Kinases: From Molecular to Pathological Features. Cells 12:12, pages 1649.
Crossref
Muhammad Bilal Azmi, Fearoz Khan, Uzma Asif, Beenish Khurshid, Abdul Wadood, Shamim Akhtar Qureshi, Syed Danish Haseen Ahmed, Hina Akram Mudassir, Sadia Ikhlaque Sheikh & Nazia Feroz. (2023) In Silico Characterization of Withania coagulans Bioactive Compounds as Potential Inhibitors of Hydroxymethylglutaryl (HMG-CoA) Reductase of Mus musculus . ACS Omega 8:5, pages 5057-5071.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.